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ABSTRACT 
Aggregation of guinea-pig macrophages within 6 hr of incubation was detected in human 
sera from patients with erythroderma, erythema multiforme, and erythema nodosum, but 
not in controls or patients with other diseases. In addition, all seven erythrodermic patients 
showed a substance in their sera that produced erythema in guinea-pig skin. This 
phenomenon may result from overproduction of mediators of cellular immunity. 
The discovery of some mediators of cell-
mediated immunity (CMI) has enhanced the 
understanding of the delayed immune response [1, 
2 ]. These mediators are released from sensitized 
lymphocytes upon interaction with a specific 
antigen. In vivo these mediators are known to both 
inhibit and activate the migrating macrophage 
(migration-inhibition factor-MIF), injure target 
cells (lymphotoxin), attract macrophages into the 
site of the response (chemotactic factor), and 
induce blast transformation in nonsensitized lym-
phocytes (blastogenic factor). Each of these steps 
is important in mobilization of the host response 
to a foreign antigen. 
There is no direct evidence that exfoliative 
erythroderma is a cutaneous manifestation of an 
immune response. However, the possibility does 
exist in view of the following information: (1) The 
onset of exfoliative erythroderma is frequently 
preceded by some type of drug eruption [3 ]; (2) a 
localized dermatitis can become an exfoliative 
erythroderma, especially if it becomes inflamed 
[3 ]; (3) chronic exfoliative erythroderma has an 
associated increase in total gamma globulin levels 
with an increase in the size of lymph nodes [4, 5 ]; 
( 4) withdrawal of the offending antigen, whether it 
be endogenous such as a tumor or exogenous such 
as the ingestion of iodid~s, may lead to resolution 
of the exfoliative erythroderma. 
Because we felt that exfoliative erythroderma 
may result from an overproduction of some of the 
mediators of cellular immunity, we postulated 
that the presence of these mediators might be 
detected in the sera of such patients. The prelimi-
nary detection of macrophage aggregation factor 
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(MAF) activity in the sera of two patients with 
exfoliative erythroderma led us to investigate 
other patients with exfoliative erythroderma as 
well as other diseases. Particularly, we were 
prompted to investigate erythema nodosum and 
erythema multiforme, two other diseases thought, 
on the basis of inconclusive evidence, to be allergic 
reaction patterns in the skin [6 ]. The presumed 
allergic etiology of erythema nodosum has been 
based on the following findings: (1) Children with 
tuberculosis do not develop erythema nodosum 
until their skin tests become strongly positive (7 ], 
and similarly, (2) patients with coccidiodomycosis 
do not develop erythema nodosum until their skin 
tests become positive and their symptoms have 
been present 1-2 weeks [6], (3) recurrences of 
erythema nodosum in patients with lympho-
granuloma venereum have been produced by in-
tracutaneous injection of the Frei antigen [8 ]. 
Evidence for an allergic mechanism in erythema 
multiforme is suggested by production of skin 
lesions experimentally by intradermal skin testing 
with a formaldehyde-inactivated herpes simplex 
antigen [9] and by the common relationship 
between the syndrome and drug hypersensitivity 
[6]. 
MAF is a mediator of cellular immunity which 
has been intensively studied and correlated with 
delayed hypersensitivity in humans and guinea 
pigs [10 ]. MAF has been demonstrated to corre-
late with in vivo delayed skin texts both in 
humans and animals but not with humoral anti-
body formation [10-12]. A less-well-defined me-
diator skin reactive factor (SRF) is also produced 
during a CMI response. It will cause guinea pigs' 
skin to become erythematous in 4-5 hr when an 
active supernatant fraction is injected intrader-
mally [13, 14 ]. 
This communication describes the results of a 
preliminary study of the presence of MAF -like 
and SRF -like activity in sera of human subjects, a 
heretofore undescribed phenomenon. 
MATERIALS AND METHODS 
Human sera were heat-inactivated at 56° C for 30 min 
to destroy complement activity and stored at -70° C. 
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Peritoneal exudate cells (PECs) were harvested from 
female Hartley strain albino guinea pigs 3 to 5 days after 
the injection of 15-20 ml of sterile light mineral oil 
intraperitoneally. The animals were sacrificed and cells 
collected by flushing the peritoneal cavity with 100-150 
ml of Hanks' balanced salt solution (Colorado Serum 
Co.) with 5 units/ml of heparin added. MAF was assayed 
according to Gotoff [15 ]. 
After the mineral oil was removed from the cells with 
a separatory funnel, the cells were washed twice in 
Hanks' balanced salt solution. Since erythrocytes inter-
fere with aggregation, if present, they were hemolyzed by 
suspending them in hypotonic (0.3%) saline for 2 min. 
The PECs were then suspended in RPMI-1640 media 
(Grand Island Biological Co.) with 20% fetal calf serum 
(Colorado Serum Co.), 50 Jlgm/ml of streptomycin and 
50 units/ml of penicillin. A cell count was carried out 
and trypan blue exclusion viability determined. Viabil-
ity of PECs was 90-98 percent by this method. PECs 
were added to 0.5 ml of both control and abnormal sera 
to final concentration of 3 x 106 PECs in a final volume 
of 1.0 ml in plastic tubes (15 x 100 mm, Falcon Plastics 
Inc.) and incubated at 37° C with 5% C0 2 and 100% 
humidity for 6 hr. All sera were assayed in duplicate. 
The sera plus PECs were observed as unknowns by 
two observers for macrophage aggregation and graded 
0 to 4+ following the criteria of Gotoff [15). Independent 
observations by two observers have consistently been 
the same. 4+ aggregation represented large aggregates 
still adhering to the plastic tubes after three gentle 
tippings. 3+ to 1+ aggregation represented diminishing 
size of aggregates and decreased adherence to plastic 
tubes. Positive controls consisted of supernatants 
known to have MAF activity prepared from sensitized 
non-adherent PECs plus antigen [15]. 
MAF-positive sera, MAF-negative sera, and control 
sera were tested for evidence of skin reactive factor 
(SRF) by injecting 0.1 cc intradermally into the shaved 
flank of guinea pigs. The skin erythema was measured 
and recorded 4 hr later. 
RESULTS 
A total of nine patients with exfoliative ery-
throderma were studied, seven prior to therapy 
and two during therapy with systemic steroids. 
Five of the seven untreated exfoliative ery-
throderma patients had positive MAF detectable 
in their sera (Fig.). Of these cases, three had 
exfoliative erythroderma secondary to atopic der-
matitis, one was associated with an apparent drug 
eruption, and the other occurred in a patient with 
a papillary renal carcinoma (Table). The latter 
case, a 67 -year-old man had exfoliative ery-
throderma for 8 months and had MAF activity in 
his sera 2 weeks before tumor removal. The day 
after his renal tumor was removed his ery-
throderma began to clear and his sera no longer 
showed MAF activity. Four months later his skin 
remained clear and no serum MAF activity was 
detected. A 16-year-old girl with exfoliative ery-
throderma secondary to atopic dermatitis had a 
similar reversion of serum MAF activity from 4+ 
to 0 as her skin cleared (Table). The two patients 
who had exfoliative erythroderma and were 
treated with systemic steroids displayed no evi-
dence of MAF activity in their sera. 
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FIG. Results of MAF determinations on heat-inac-
tivated human sera in healthy control subjects, ery-
throderma, erythema multiforme, erythema nodosum, 
and other diseases. The clear circles represent patients 
receiving systemic steroids during the time when sera 
were tested . 
TABLE 
Results of MAF and SRF determinations on 
heat-inactivated human sera in patients with 
erythroderma, erythema multiforme, and erythema 
nodosum 
SRF 
Diagnosis Associated Age Sex MAF (mm Disease ery-
them a) 
frythroderma renal tumor 67 M 4+ N.D. 
Erythroderma tumor removed 0 N.D. 
Erythroderma 4 months later 0 N.D. 
*Erythroderma psoriasis 56 M 0 13 
Erythroderma drug eruption 24 F 2+ 20 
*Erythroderma lymphoma 70 F 0 17 
Erythroderma atopy 50 M 4+ 22 
Erythroderma atopy 52 M 1+ 24 
{Erythroderma atopy 16 F 4+ N.D. 
Erythroderma cleared 0 N.D. 
Erythroderma none 71 M 0 11 
Erythroderma drug eruption 68 M 0 16 
E. Multiforme none 21 F 4+ N.D. 
E. Multiforme drug eruption 6 M 0 12 
E. Multiforme none 36 F 3+ 19 
E. Multiforme drug eruption 18 F 0 9 
E. Multiforme none 42 M 0 N.D. 
E. Nodosum none 18 F 4+ N.D. 
E. Nodosum drug eruption 20 F 1+ N.D. 
E. Nodosum none 58 .F 2+ 3 
Multiple assays from single patients indicated by 
brackets 
N.D. = not done 
* = patient treated with systemic steroids when 
serum was tested 
All three patients with erythema nodosum had 
MAF activity in their sera. One was treated with 
intralesional steroids before MAF determination 
but none was treated with systemic steroids (Ta-
ble). 
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Two of the five patients with erythema mul-
tiforme had MAF-positive sera (Table). Eight 
normal subjects without cutaneous or systemic 
disease did not show MAF activity in their sera 
nor did 22 patients with other diseases: untreated 
systemic lupus erythematosus (8), psoriasis (3), 
dyshidrotic eczema (3), pyoderma gangrenosum 
(1), Weber-Christian disease (1), lichen planus 
(1), active tuberculosis (1), mild atopic dermatitis 
(2), pemphigus foliaceous (1), toxic epidermal 
necrolysis ( 1) (Fig.). Eight additional untreated 
patients with systemic inflammatory diseases ( 4 
with bullous pemphigoid, 2 with pemphigus folia-
ceous, and 2 with pemphigus vulgaris) had no 
evidence of MAF activity in their sera. They were 
selected because of high antibody titers, two 
patients with bullous pemphigoid had titers of 
1 : 10,240 of antibasement membrane antibodies. 
These patients were not included in the Figure. 
Two patients who were undergoing rejection of 
renal homografts were being treated with steroids 
as well as other immunosuppressives and had no 
evidence of MAF activity in their sera. 
Of 46 sera tested for MAF activity, 22 were 
assayed for SRF activity. Six sera from healthy 
controls and five sera from other patients with 
other diseases (psoriasis, 2; lichen planus, 1; 
atopic dermatitis, 1; and dyshidrotic eczema, 1) 
showed less than 10 mm of erythema at 4 hr. Each 
of the seven sera from patients with exfoliative 
erythroderma tested (Table) had greater than 10 
mm of erythema at 4 hr. To be noted is the fact 
that four patients with exfoliative erythroderma 
had SRF activity but no MAF activity. These skin 
tests were identical to two MAF -positive superna-
tant fractions obtained from lympocyte-rich gui-
nea-pig PECs (and antigen), prepared as de-
scribed by Gotoff [15] using a method similar to 
that of Bennett and Bloom who produced SRF 
originally [13 ]. All control sera had less than 10 
mm of erythema as did the supernatant fractions 
from sensitized guinea-pig lymphocytes cultured 
without antigen. 
Erythema multiforme patients had a positive 
reaction for SRF activity in two of the three cases 
tested (Table). One sera that was negative for 
MAF activity was positive for SRF activity. Con-
versely, a patient with erythema nodosum had 
positive MAF activity and negative SRF activity 
(Table). 
DISCUSSION 
MAF was recently described by Lolekha et al 
[15] and is very similar, if not identical, to MIF 
which is known to inhibit the migration of macro-
phages [1 ]. SRF is known to cause skin erythema 
[14] ~md is apparently produced by the same 
process that produces MAF [13 ]. SRF shows peak 
erythema at different times in different systems. 
In our studies peak erythema occurred at 4 hr and 
was diminished at 24 hr, which corresponds best 
to the system of Pick et al [16 ], but was earlier 
than the SRF detected by Bennett and Bloom 
[13 ], Schwartz and Leon [17 ], and Ramseier [18 ]. 
Although it is generally unwise to cross species 
when determining skin erythema as we did in 
injecting human sera into guinea-pig skin, our 
controls and positive sera were clearly separated. 
It would certainly seem plausible that condi-
tions could exist where excess MAF is released, 
resulting in inhibition and activation of migrating 
macrophages and the accumulation of a cellular 
infiltrate in the skin. This process could explain 
why lesions such as erythroderma, erythema no-
dosum, and erythema multiforme occur. Whether 
the phenomenon of macrophage aggregation ac-
tivity and skin reactive activity in the sera of 
patients with erythroderma, erythema mul-
tiforme, and erythema nodosum may be the result 
of the overproduction of mediators of cellular 
immunity in these patients remains to be deter-
mined. We recognize that substances other than 
mediators of cellular immunity may be responsibe 
for aggregation of guinea-pig macrophages and 
erythema of guinea pigs' skin. 
All patients with exfoliative erythroderma and 
erythema multiforme that had a positive MAF 
activity showed positive SRF activity. In contrast, 
the one serum that showed MAF activity and no 
SRF activity was from a patient with erythema 
nodosum. Unfortunately we did not collect enough 
sera to test all of it for SRF activity. 
It is our observation that MAF activity de-
creased with repeated freezing and thawing of the 
serum. The serum retains MAF activity for at 
least 4 months if kept frozen at -70° C. Unpub-
lished observations in our laboratory have repeat-
edly confirmed that the presence of pharmacologic 
concentrations of corticosteroids inhibits the in 
vitro macrophage aggregation factor assay. This 
may account for a negative MAF assay in patients 
receiving systemic steroids. 
Although we have no confirmatory evidence 
that the phenomenon of guinea-pig macrophage 
aggregation and skin erythema is in fact due to 
release of mediators of cellular immunity, this 
finding may provide new avenues for investigation 
into the mechanisms by which these skin reac-
tions are produced. 
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